Nervous System News and Research

Latest Nervous System News and Research

Brain lesion scan appearance shows increased multiple sclerosis activity during spring and summer

New research shows that multiple sclerosis (MS) activity can increase during spring and summer months. The research is published in the August 31, 2010, issue of Neurology, the medical journal of the American Academy of Neurology.

31 Aug 2010

SIR issues position statement to determine safety, effectiveness of interventional M.S. treatment

Recognizing that venous interventions may potentially play an important role in treating some patients who suffer from multiple sclerosis an incurable, disabling disease the Society of Interventional Radiology has issued a position statement indicating its support for high quality clinical research to determine the safety and effectiveness of interventional M.S. treatments.

31 Aug 2010

Smoked cannabis relieves chronic neuropathic pain

The medicinal use of cannabis has been debated by clinicians, researchers, legislators and the public at large for many years as an alternative to standard pharmaceutical treatments for pain, which may not always be effective and may have unwanted side effects. A new study by McGill University Health Centre (MUHC) and McGill University researchers provides evidence that cannabis may offer relief to patients suffering from chronic neuropathic pain.

30 Aug 2010

FDA approves additional strengths of SOLODYN for inflammatory lesions treatment

Medicis today announced that the U.S. Food and Drug Administration (FDA) has approved additional strengths of SOLODYN (minocycline HCl, USP) Extended Release Tablets in 55 mg, 80 mg and 105 mg dosages for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older.

30 Aug 2010

Latest achievements in brain research and treatment for mental disorders

Mental disorders, such as depression, anxiety disorders, addiction and schizophrenia are the core challenge of most health care systems around the world. In the EU alone, each year 27% of the total adult population - this corresponds to 83 Million citizens - suffer from mental disorders. Depression alone affects almost 20 million ranking in the EU as the most disabling disorder of all diseases.

30 Aug 2010

Researchers find smoked cannabis reduces chronic neuropathic pain

For people suffering chronic pain, smoked cannabis reduces pain, improves mood and helps sleep, according to new research published in CMAJ.

30 Aug 2010

TEMSO Phase III Trial shows ARR reduction in multiple sclerosis patients

Sanofi-aventis announced today that the investigational once-daily oral drug teriflunomide significantly reduced annualized relapse rate (ARR) at 2 years versus placebo in patients with relapsing multiple sclerosis (RMS), thus achieving the primary endpoint in the TEMSO phase III trial.

30 Aug 2010

Orexigen Therapeutics board approves grant of inducement stock options

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that on August 25, 2010 the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 10,000 shares of common stock to two new employees.

27 Aug 2010

FDA approves Novartis' Tekamlo for treatment of high blood pressure

The US Food and Drug Administration (FDA) approved Tekamlo™ (aliskiren and amlodipine) tablets, a single-pill for the treatment of high blood pressure combining the only approved direct renin inhibitor, Tekturna® (aliskiren), with the widely used calcium channel blocker amlodipine. Tekamlo is approved as initial therapy for patients who are likely to need multiple drugs to achieve their blood pressure goals, and as replacement therapy for patients whose blood pressure is not adequately controlled with either aliskiren or amlodipine alone.

27 Aug 2010

KemPharm broadens protection for LAT prodrug technology platform for ADHD with second patent

KemPharm, Inc. announced today that it has received a Notice of Issuance from the United States Patent and Trademark Office (USPTO) for its patent application entitled "Non-Standard Amino Acid Conjugates of Amphetamine and Processes for Making and Using the Same", U.S. Patent No. 7,776,917 B2. This patent, combined with KemPharm's recently issued U.S. Patent No. 7,772,222, provides broad protection of the Company's Ligand Activated Therapy (LAT) prodrug technology platform and its application to the treatment of Attention Deficit – Hyperactivity Disorder.

27 Aug 2010

'Neural inertia' may explain brain's resistance to changes in consciousness

Despite the fact that an estimated 25 million patients per year in the U.S. undergo surgeries using general anesthesia, scientists have only been able to hypothesize exactly how anesthetics interact with the central nervous system. They previously thought that the processes of "going under" and waking up from anesthesia affected the brain in the same way.

27 Aug 2010

Researchers recommend traumatic brain injury reclassification for additional funding

Traumatic brain injury, currently considered a singular event by the insurance industry and many health care providers, is instead the beginning of an ongoing process that impacts multiple organ systems and may cause or accelerate other diseases and disorders that can reduce life expectancy, according to research from the University of Texas Medical Branch at Galveston.

27 Aug 2010

Disulfiram drug effective in treating cocaine addiction: Research

Doctors have used the drug disulfiram to help patients stay sober for several decades. It interferes with the body's ability to metabolize alcohol, giving a fierce hangover to someone who consumes even a small amount of alcohol.More recently, disulfiram was shown to be effective in treating cocaine addiction as well, even though alcohol and cocaine affect the nervous system in different ways.

27 Aug 2010

Vanda Pharmaceuticals initiates tasimelteon Phase III clinical trial for Non-24-Hour Sleep Wake Disorder

Vanda Pharmaceuticals Inc., today announced it has initiated a Phase III clinical trial to evaluate tasimelteon in patients with Non-24-Hour Sleep Wake Disorder (N24HSWD), a condition experienced primarily by totally blind individuals that results in abnormal night sleep patterns and chronic daytime sleepiness.

26 Aug 2010

Alexza Pharmaceuticals licenses Staccato nicotine technology to Cypress Bioscience

Alexza Pharmaceuticals, Inc. announced today that it has licensed its Staccato nicotine technology to Cypress Bioscience, Inc. The Staccato nicotine technology is a novel electronic multidose delivery system designed to help people stop smoking. The Staccato nicotine technology is intended to improve on a well-validated smoking cessation approach by delivering nicotine via inhalation, mimicking the nicotine effects of smoking without the harmful side effects associated with cigarettes.

26 Aug 2010

23rd European College of Neuropsychopharmacology Congress to be held 28 Aug - 1 Sep 2010 in Amsterdam

26 Aug 2010

Critical mechanistic link between mutant protein and disease pathogenesis in ALS uncovered

New research uncovers what may be a primary neuron-damaging insult that occurs in an inherited form of a devastating neurodegenerative disorder. The study, published by Cell Press in the August 26th issue of the journal Neuron, describes a critical mechanistic link between a mutant protein and disease pathogenesis in an animal model of amyotrophic lateral sclerosis (ALS).

26 Aug 2010

Neuralstem files IND with FDA for spinal cord stem cell Phase I clinical trial for chronic spinal cord injury

Neuralstem, Inc. announced that it has filed an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) to begin a Phase I safety clinical trial for chronic spinal cord injury with its spinal cord stem cells. This multicenter Phase I safety trial will enroll a total of 16 long-term, or chronic, spinal cord injury patients, with an American Spinal Injury Association (ASIA) Grade A level of impairment, one-to-two years post-injury.

26 Aug 2010

Type 2 diabetes, insulin resistance increases risk for Alzheimer's disease: Research

People with insulin resistance and type 2 diabetes appear to be at an increased risk of developing plaques in the brain that are associated with Alzheimer's disease, according to new research published in the August 25, 2010, issue of Neurology, the medical journal of the American Academy of Neurology.

26 Aug 2010

Ataxin 2 gene mutation contributes to Lou Gehrig's disease: Research

An international study led by biologists and neuroscientists from the University of Pennsylvania has identified a new genetic risk factor for amyotrophic lateral sclerosis, commonly known as ALS or Lou Gehrig's disease.

26 Aug 2010

Nervous System News and Research

Latest Nervous System News and Research

Brain lesion scan appearance shows increased multiple sclerosis activity during spring and summer

SIR issues position statement to determine safety, effectiveness of interventional M.S. treatment

Smoked cannabis relieves chronic neuropathic pain

FDA approves additional strengths of SOLODYN for inflammatory lesions treatment

Latest achievements in brain research and treatment for mental disorders

Researchers find smoked cannabis reduces chronic neuropathic pain

TEMSO Phase III Trial shows ARR reduction in multiple sclerosis patients

Orexigen Therapeutics board approves grant of inducement stock options

FDA approves Novartis' Tekamlo for treatment of high blood pressure

KemPharm broadens protection for LAT prodrug technology platform for ADHD with second patent

'Neural inertia' may explain brain's resistance to changes in consciousness

Researchers recommend traumatic brain injury reclassification for additional funding

Disulfiram drug effective in treating cocaine addiction: Research

Vanda Pharmaceuticals initiates tasimelteon Phase III clinical trial for Non-24-Hour Sleep Wake Disorder

Alexza Pharmaceuticals licenses Staccato nicotine technology to Cypress Bioscience

23rd European College of Neuropsychopharmacology Congress to be held 28 Aug - 1 Sep 2010 in Amsterdam

Critical mechanistic link between mutant protein and disease pathogenesis in ALS uncovered

Neuralstem files IND with FDA for spinal cord stem cell Phase I clinical trial for chronic spinal cord injury

Type 2 diabetes, insulin resistance increases risk for Alzheimer's disease: Research

Ataxin 2 gene mutation contributes to Lou Gehrig's disease: Research

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Nervous System News and Research

Latest Nervous System News and Research

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in